… demonstrated in several cancers, and TLR agonists are now … agonists as single agent
immunomodulators, vaccine adjuvants and in combination with conventional cancer therapies. …

… The activation of cell surface death receptors by tumor … ) and death receptor agonists represent
an attractive therapeutic … and agonist monoclonal antibodies that target death receptors 4 …

Toll-like receptors (TLRs) have long been known for their ability to initiate innate immune
responses upon exposure to conserved microbial components such as lipopolysaccharide (…

Toll-like receptors (TLRs) are prototypic pattern recognition receptors (PRRs) best known
for their ability to activate the innate immune system in response to conserved microbial …

… have been approved by regulatory agencies for use in cancer … and clinical development
of TLR agonists for cancer therapy. … on the development of TLR agonists for cancer therapy. …

… cognate immune system against cancer cells. Today, only three TLr agonists are approved
by … /are evaluating FDA-approved TLr agonists as off-label medications for cancer therapy. …

… may offer a novel strategy to treat cancer. In this chapter we … cancer, and provide novel
suggestions for the development, exploration and use of cannabinoid agonists for cancer therapy, …

… agonists in cancer therapy, it is essential to elucidate signaling pathways induced by TLRs
before their employment in therapy … agonists in the development of novel antitumor therapies. …

… or co-repressor are responsible for their agonist or antagonistic activities, the overall picture,
… of estrogen receptor agonists/s which are used for the treatment of breast cancer. SERMs …

… as cancer therapeutics, though the widespread clinical use and low toxicity of M3
antagonists support the potential role of these drugs as adjuvants to current cancer therapies. …